Laboratory Corp of America Holdings (LH) Stock Price, Quote & News

Company Profile

Labcorp Holdings Inc. provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid, PAP, hemoglobin A1C, prostate-specific antigens, sexually transmitted diseases, hepatitis C, vitamin D, microbiology cultures and procedures, and alcohol and other substance-abuse tests. It also provides specialty testing services comprising gene...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 336-584-5171

Fax: 336-436-1569

Website: www.labcorp.com

Address:

531 South Spring Street, Burlington, United States

AtomicAIerts Dec. 5 at 6:21 AM

$LH AtomicAlerts Scalp Alert Direction: SHORT Entry: $261.42 TP1: $260.72 | TP2: $260.02 | TP3: $259.32 Stop Loss: $262.02 👉 https://atomicalerts.com

0 · Reply

Iightning Dec. 5 at 1:37 AM

1ightning® Premium Options Alert (Actionable) Ticker: $LH Contract: Dec 19 $270C Entry: 2.08 Exit: 3.64 Return: +75.29% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Iightning Dec. 4 at 8:08 PM

1ightning® Premium Options Alert (Actionable) Ticker: $LH Contract: Dec 19 $270C Entry: 2.08 Exit: 3.64 Return: +75.29% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

AtomicAIerts Dec. 4 at 4:40 PM

$LH AtomicAlerts® Scalp Alert Direction: SHORT Entry: $262.39 TP1: $261.69 | TP2: $260.99 | TP3: $260.29 Stop Loss: $262.99 EMA9: 262.42 | EMA21: 262.39 RSI14: 44.78 | VWAP: 265.15 Paid Alerts: https://atomicalerts.com

0 · Reply

AtomicAIerts Dec. 4 at 3:05 PM

$LH AtomicAlerts® Scalp Alert Direction: SHORT Entry: $260.99 TP1: $260.29 | TP2: $259.59 | TP3: $258.89 Stop Loss: $261.59 EMA9: 261.29 | EMA21: 261.98 RSI14: 36.76 | VWAP: 266.0 Paid Alerts: https://atomicalerts.com

0 · Reply

AtomicAIerts Dec. 4 at 1:29 PM

$LH AtomicAlerts® Scalp Alert Direction: SHORT Entry: $265.67 TP1: $264.97 | TP2: $264.27 | TP3: $263.57 Stop Loss: $266.27 EMA9: 265.73 | EMA21: 265.95 RSI14: 34.29 | VWAP: 266.47 Paid Alerts: https://atomicalerts.com

0 · Reply

AtomicAIerts Dec. 4 at 11:56 AM

0 · Reply

Iightning Dec. 4 at 3:51 AM

1ightning® Premium Options Alert (Actionable) Ticker: $LH Contract: Dec 19 $270C Entry: 2.95 Exit: 5.32 Return: +80.19% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

BillionerOfKing Dec. 3 at 1:36 AM

$LH Current Stock Price: $265.99 Contracts to trade: $270 LH Dec 19 2025 Call Entry: $2.90 Exit: $3.77 ROI: 30% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

ZacksResearch Dec. 2 at 1:10 PM

$LH outperforms the industry — but is it a hold or buy? 🤔 Despite a Zacks Rank #3, Labcorp's strategic expansions in oncology and genetic testing are noteworthy alongside a 16.8% rally over the past year, outpacing the industry's 9.4% growth. Yet, macroeconomic challenges and currency headwinds loom. Discover the full investment case here 👉 https://www.zacks.com/stock/news/2798098/should-you-continue-to-hold-lh-stock-in-your-portfolio?cid=sm-stocktwits-2-2798098-body-22983&ADID=SYND_STOCKTWITS_TWEET_2_2798098_BODY_22983

0 · Reply

Community Health Systems Completes Sale of Select Outreach Laboratory Assets to Labcorp

CYH

Nov 24, 2025, 8:30 AM EST - 10 days ago

Labcorp Appoints Victor Bulto to Board of Directors

Nov 19, 2025, 7:04 AM EST - 15 days ago

Labcorp® Plasma Detect™ Clinical Studies Featured in Nature Medicine and Clinical Cancer Research

Nov 17, 2025, 9:00 AM EST - 17 days ago

Lunit and Labcorp Announce Strategic Collaboration to Advance AI-Powered Digital Pathology Research

Oct 28, 2025, 2:45 PM EDT - 5 weeks ago

Labcorp Positioned For Gradual Upside With Resilient Margins And Dividend Support

Oct 28, 2025, 12:31 PM EDT - 5 weeks ago

Labcorp Holdings Inc. (LH) Q3 2025 Earnings Call Transcript

Oct 28, 2025, 6:52 AM EDT - 5 weeks ago

Labcorp lifts annual profit forecast on strong diagnostic test demand

Oct 28, 2025, 6:50 AM EDT - 5 weeks ago

Labcorp Announces 2025 Third Quarter Results

Oct 23, 2025, 7:00 AM EDT - 6 weeks ago

Labcorp to Offer First FDA-Cleared Blood Test to Rule out Alzheimer's-Related Amyloid Pathology in Primary Care Settings

Oct 20, 2025, 9:00 AM EDT - 6 weeks ago

Praia Health, Providence, and Labcorp Collaborate to Transform Patient Engagement and Lab Order Adherence

Oct 8, 2025, 4:15 PM EDT - 2 months ago

Labcorp Declares Quarterly Dividend

Sep 30, 2025, 7:00 AM EDT - 2 months ago

Labcorp Announces Collaboration with Roche to Advance Digital Pathology Capabilities

Sep 25, 2025, 4:15 PM EDT - 2 months ago

Labcorp to Announce Third Quarter Financial Results on October 28, 2025

Sep 15, 2025, 8:30 AM EDT - 2 months ago

Labcorp Completes Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses

OPK

Sep 9, 2025, 10:26 AM EDT - 3 months ago

Labcorp Holdings Inc. (LH) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Aug 27, 2025, 4:15 PM EDT - 3 months ago

Labcorp to Speak at the Morgan Stanley 23rd Annual Global Healthcare Conference

Aug 18, 2025, 7:00 AM EDT - 3 months ago

Labcorp Launches First FDA-Cleared Blood Test for Alzheimer's Disease

Jul 30, 2025, 7:12 AM EDT - 4 months ago

Labcorp Introduces Test Finder, a First-of-Its-Kind Generative AI Tool to Simplify Lab Test Search

Jul 29, 2025, 7:00 AM EDT - 4 months ago

Labcorp Achieves IVDR CE-Marking for PGDx elio™ tissue complete in the EU

Jul 25, 2025, 9:45 AM EDT - 4 months ago

These Analysts Boost Their Forecasts On Labcorp Following Better-Than-Expected Q2 Earnings

Jul 24, 2025, 6:12 PM EDT - 4 months ago

Labcorp Posts 9.5 Percent Gain in Q2

Jul 24, 2025, 2:38 PM EDT - 4 months ago

Labcorp Holdings Inc. (LH) Q2 2025 Earnings Call Transcript

Jul 24, 2025, 12:27 PM EDT - 4 months ago

Why Is Testing Giant Labcorp Stock Surging On Thursday?

Jul 24, 2025, 7:00 AM EDT - 4 months ago

Labcorp raises annual profit forecast on strong diagnostic testing demand

Jul 24, 2025, 6:50 AM EDT - 4 months ago

Labcorp Announces 2025 Second Quarter Results

Jul 22, 2025, 4:15 PM EDT - 4 months ago

Community Health Systems Announces Definitive Agreement to Sell Select Outreach Laboratory Assets to Labcorp

CYH

Jun 30, 2025, 6:58 AM EDT - 5 months ago

Labcorp Upgraded To A Buy As Portfolio Grows And Leverage Stays Low

Jun 26, 2025, 4:10 PM EDT - 5 months ago

Labcorp to Announce Second Quarter Financial Results on July 24, 2025

Jun 2, 2025, 7:00 AM EDT - 6 months ago

ASU, Labcorp, and InStride announce first-of-its-kind diagnostics industry partnership that tackles critical healthcare workforce shortage

May 30, 2025, 7:00 AM EDT - 6 months ago

Labcorp Expands Oncology Portfolio to Improve Patient Care and Advance Cancer Research

May 8, 2025, 4:15 PM EDT - 7 months ago

Labcorp to Webcast Its Annual Meeting of Shareholders May 15

Apr 29, 2025, 4:21 PM EDT - 7 months ago

Labcorp Holdings Inc. (LH) Q1 2025 Earnings Call Transcript

Apr 29, 2025, 6:56 AM EDT - 7 months ago

Labcorp beats quarterly profit estimate on diagnostic test demand

Apr 29, 2025, 6:50 AM EDT - 7 months ago

Labcorp Announces 2025 First Quarter Results

Apr 23, 2025, 7:00 AM EDT - 8 months ago

Labcorp Launches Molecular Residual Disease and Liquid Biopsy Solutions

Apr 11, 2025, 5:32 AM EDT - 8 months ago

Genetic Screening Testing for the Preventive Health Market, 2025-2035 Analysis - Dominated by Exact Science, Labcorp Genetics, Blueprint Genetics, Ambry Genetics, and Genex Diagnostics

Apr 2, 2025, 7:00 AM EDT - 8 months ago

Labcorp Launches First-of-its-Kind Immunoassay to Accelerate Path to Diagnosis of Alzheimer's Disease

Apr 1, 2025, 8:32 AM EDT - 8 months ago

Labcorp to Offer HPV and STI Self-Collection Options in Labcorp Patient Service Centers and Participating Physician Offices Nationwide

Mar 31, 2025, 4:15 PM EDT - 8 months ago

Labcorp to Announce First Quarter Financial Results on April 29, 2025

Mar 11, 2025, 7:00 AM EDT - 9 months ago

Labcorp Announces Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses

OPK

Feb 24, 2025, 7:32 AM EST - 10 months ago

Labcorp Announces Clinical Availability of Liquid Biopsy Test to Guide Personalized Treatment Plans for Patients with Advanced Solid Tumors

Feb 13, 2025, 2:12 PM EST - 10 months ago

Labcorp Holdings: Focus On Core Strengths For Future Growth, Initiate At 'Hold'

Feb 6, 2025, 3:42 PM EST - 10 months ago

Labcorp Holdings Inc. (LH) Q4 2024 Earnings Call Transcript

Feb 6, 2025, 1:22 PM EST - 10 months ago

Labcorp Q4 Earnings: Revenue And EPS Beat, Expects Strong 2025 Growth, Analyst Reiterates Outperform On Stable 2025 Outlook

Feb 6, 2025, 6:55 AM EST - 10 months ago

Labcorp forecasts 2025 revenue above estimates on diagnostic test demand

Feb 6, 2025, 6:50 AM EST - 10 months ago

Labcorp Announces 2024 Fourth Quarter and Full Year Results

Jan 10, 2025, 4:15 PM EST - 11 months ago

Labcorp to Speak at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 8, 2025, 6:02 PM EST - 11 months ago

LABCORP DECLARES QUARTERLY DIVIDEND

Jan 8, 2025, 4:15 PM EST - 11 months ago

Labcorp to Announce Fourth Quarter Financial Results on February 6, 2025

Jan 8, 2025, 8:15 AM EST - 11 months ago

Geneoscopy Closes $105M in Series C Funding Round to Power Next-Generation of Gastrointestinal Diagnostic Tests

BIO

AtomicAIerts Dec. 5 at 6:21 AM

$LH AtomicAlerts Scalp Alert Direction: SHORT Entry: $261.42 TP1: $260.72 | TP2: $260.02 | TP3: $259.32 Stop Loss: $262.02 👉 https://atomicalerts.com

0 · Reply

Iightning Dec. 5 at 1:37 AM

1ightning® Premium Options Alert (Actionable) Ticker: $LH Contract: Dec 19 $270C Entry: 2.08 Exit: 3.64 Return: +75.29% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

Iightning Dec. 4 at 8:08 PM

1ightning® Premium Options Alert (Actionable) Ticker: $LH Contract: Dec 19 $270C Entry: 2.08 Exit: 3.64 Return: +75.29% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

AtomicAIerts Dec. 4 at 4:40 PM

0 · Reply

AtomicAIerts Dec. 4 at 3:05 PM

0 · Reply

AtomicAIerts Dec. 4 at 1:29 PM

0 · Reply

AtomicAIerts Dec. 4 at 11:56 AM

0 · Reply

Iightning Dec. 4 at 3:51 AM

1ightning® Premium Options Alert (Actionable) Ticker: $LH Contract: Dec 19 $270C Entry: 2.95 Exit: 5.32 Return: +80.19% ROI Unlock VIP Access → https://1ightning.com

0 · Reply

BillionerOfKing Dec. 3 at 1:36 AM

0 · Reply

ZacksResearch Dec. 2 at 1:10 PM

0 · Reply

ZacksResearch Dec. 2 at 11:57 AM

Is $LH still worth holding here? ⚠️ When the headline itself is asking if you should “continue to hold,” that’s a clear signal this name is at an inflection point that investors can’t ignore. The full breakdown on whether LH still earns a spot in your portfolio 👉 https://www.zacks.com/stock/news/2798098/should-you-continue-to-hold-lh-stock-in-your-portfolio?cid=sm-stocktwits-2-2798098-teaser-22957&ADID=SYND_STOCKTWITS_TWEET_2_2798098_TEASER_22957

0 · Reply

Iightning Dec. 1 at 10:03 PM

**1ightning® Premium Options Alert (Actionable)** **Ticker:** $LH **Contract:** Dec 19 $270C **Entry:** 5.42 **Exit:** 8.27 **Return:** **+52.52% ROI** This is the level of accuracy our VIP desk delivers daily. If you want **institutional-grade scalps without the noise**, join us. **Unlock VIP Access → https://1ightning.com**

0 · Reply

Iightning Nov. 26 at 12:49 AM

1ightning® Options Trade Alert (Actionable) | Buy $LH Dec 19 $270 Call | Enter: $3.85 Exit: $6.83 | Profit: 77.41% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 25 at 10:56 AM

1ightning® Options Trade Alert (Actionable) | Buy $LH Dec 19 $270 Call | Enter: $3.85 Exit: $6.83 | Profit: 77.41% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 24 at 11:51 PM

1ightning® Options Trade Alert (Actionable) | Buy $LH Dec 19 $270 Call | Enter: $3.85 Exit: $6.83 | Profit: 77.41% ROI | https://1ightning.com

0 · Reply

OfficialStocktwitsUser Nov. 24 at 2:04 PM

$LH RSI: 57.69, MACD: -2.3687 Vol: 7.63, MA20: 259.45, MA50: 271.74 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Iightning Nov. 21 at 9:09 PM

1ightning® Options Trade Alert (Actionable) | Buy $LH Dec 19 $260 Call | Enter: $7.28 Exit: $9.60 | Profit: 31.92% ROI | https://1ightning.com

0 · Reply

ZacksResearch Nov. 21 at 2:12 PM

$LH makes waves with innovative Plasma Detect tech! 🌊 📈 Featured in Nature Medicine and Clinical Cancer Research, this tech aids in predicting long-term survival and tracking early disease progression in diffuse pleural mesothelioma treatment. 🔬 Enhanced detection capabilities in post-surgery scenarios, especially for head and neck cancer. Discover how this could shape LH’s future prospects 👉 https://www.zacks.com/stock/news/2794023/lh-shares-gain-following-publication-of-new-plasma-detect-mrd-data?cid=sm-stocktwits-2-2794023-body-21987&ADID=SYND_STOCKTWITS_TWEET_2_2794023_BODY_21987

0 · Reply

ZacksResearch Nov. 21 at 1:12 PM

Big move brewing for $LH? New studies are putting Plasma Detect in the spotlight, showing its potential in tracking MRD and improving post-surgery cancer detection — and the shares are already edging higher on the news. Full breakdown here 👉 https://www.zacks.com/stock/news/2794023/lh-shares-gain-following-publication-of-new-plasma-detect-mrd-data?cid=sm-stocktwits-2-2794023-teaser-21986&ADID=SYND_STOCKTWITS_TWEET_2_2794023_TEASER_21986

0 · Reply

Iightning Nov. 21 at 12:04 AM

1ightning® Options Trade Alert (Actionable) | Buy $LH Dec 19 $260 Call | Enter: $7.28 Exit: $9.60 | Profit: 31.92% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 19 at 9:42 PM

1ightning® Options Trade Alert (Actionable) | Buy $LH Dec 19 $260 Call | Enter: $7.28 Exit: $9.60 | Profit: 31.92% ROI | https://1ightning.com

0 · Reply

Iightning Nov. 19 at 6:07 AM

1ightning® Options Trade Alert (Actionable) | Buy $LH Dec 19 $260 Call | Enter: $7.28 Exit: $9.60 | Profit: 31.92% ROI | https://1ightning.com

0 · Reply

Market Cap	22.03B
Revenue (ttm)	13.01B
Net Income (ttm)	746.00M
EPS (ttm)	N/A
PE Ratio	16.81
Forward PE	16.29
Profit Margin	5.73%
Debt to Equity Ratio	0.58

Volume	861,178
Avg Vol	834,774
Day's Range	N/A - N/A
Shares Out	82.90M
Stochastic %K	45%
Beta	0.99
Analysts	Strong Sell
Price Target	$300.70